Weight Loss Injections Near Edgbaston: What the Evidence Actually Shows

What SURMOUNT and STEP actually found, and why the numbers matter for Edgbaston patients

The headline figures from the major trials are often quoted without context, so it helps to read them carefully. In SURMOUNT-1 (2,539 adults with obesity and no diabetes, followed for 72 weeks) tirzepatide at its 15mg dose produced an average weight reduction of around 20–21%. That is not a best-case result; it is the mean across thousands of participants who also followed a reduced-calorie diet and increased activity alongside the injection. The STEP 1 trial for semaglutide 2.4mg produced an average reduction of around 15% over 68 weeks under similar conditions. Both trials have since informed NICE's guidance on tirzepatide (TA1026) and the NHS's approach to prescribing.

Results varied across individuals in both studies. People with a higher starting BMI tended to lose more in absolute kilograms but not always more in percentage terms. Weight reduction slowed after the first six months in most participants, which is why the trials ran for over a year. Neither injection is a short-term fix, the trial protocols assumed ongoing dietary and behavioural support alongside the medicine, and NICE's recommendations carry that assumption forward into UK practice.

A head-to-head trial published in the New England Journal of Medicine in 2025 (SURMOUNT-5) compared tirzepatide directly with semaglutide 2.4mg over 72 weeks. Tirzepatide produced greater average weight reduction. That data is now part of the clinical conversation, though which medicine is appropriate for a given person is always a prescriber's call, not a league-table decision. You can read more about how the two medicines differ on our overview of licensed weight loss injections, which also explains how a weight loss injection works in practice and what to expect from the treatment journey.

Who these injections are licensed for, and what the prescriber considers beyond BMI

UK licensing for both medicines sets a BMI threshold as a starting point, not the whole story. Tirzepatide is licensed for adults with a BMI of 30 or above, or from 27 if a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnoea is present. Semaglutide (Wegovy) carries similar criteria. For some ethnic backgrounds, guidance recommends applying thresholds that are 2.5 kg/m² lower (so 27.5 instead of 30, or 24.5 instead of 27) in line with evidence about cardiovascular and metabolic risk at lower BMI values.

Beyond the number on the scales, a prescriber weighs current medications, any history of pancreatitis or thyroid disease, whether you are pregnant, planning pregnancy, or breastfeeding (neither injection is recommended in those circumstances), and a range of other factors that vary from person to person. The NHS BMI calculator at nhs.uk is a useful first reference point, but it gives a number, not a clinical assessment. That assessment is what the prescription process is for.

Patients often ask whether being based in Edgbaston or elsewhere in the West Midlands changes what is available to them. For private treatment through a regulated online pharmacy, location has no bearing on eligibility, the prescriber reviews the same information regardless. For NHS access, the phased rollout means criteria currently require a BMI of 40 or above with several qualifying comorbidities, with broader access expanding gradually through 2026 and 2027. If you are in South Yorkshire and want to understand local private options, our guide to weight loss injections in Barnsley covers what to expect from the process in that area.

Side effects, safety signals, and when to seek help quickly

The most common side effects of both injections are gastrointestinal: nausea, loose stools or diarrhoea, constipation, indigestion, and a feeling of fullness that can make eating normally feel uncomfortable at first. For most people these settle within a couple of weeks of starting or after a dose increase; starting at the lowest dose is specifically designed to reduce their severity. The NHS tirzepatide medicines page lists the full side-effect profile alongside practical advice on managing common reactions.

Some side effects require prompt attention. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as a known but infrequent risk with GLP-1 medicines: severe, persistent stomach pain that spreads toward the back (with or without vomiting) warrants urgent medical attention, not a wait-and-see approach. Gallbladder problems, serious allergic reactions, and significant dehydration from prolonged vomiting or diarrhoea are also reasons to contact a clinician quickly rather than manage at home.

Any suspected side effect can be reported through the MHRA's Yellow Card scheme. That applies whether you are on a private prescription or an NHS one. Reporting helps regulators track real-world safety signals, it is a straightforward online form and takes a few minutes. If you have questions about a side effect you are already experiencing, our aftercare team is available seven days a week.

What the process looks like when you get a prescription through a regulated online pharmacy

For people who do not meet the current NHS rollout criteria, or who would rather not wait for a GP appointment and a specialist referral, a regulated online pharmacy is the other legal route. The process matters, not all providers are the same, and the GPhC register lets anyone check whether a pharmacy is registered before sharing personal health information or making a payment.

At nume, the consultation is free and takes place entirely online. A GPhC-registered Independent Prescriber (a real clinician, not an automated system) reads every submission and makes their decision the same day. Identity and weight are verified directly, not taken on trust. If treatment is approved before midday on a working day, it is dispatched the same afternoon; a plain, unbranded box arrives the next working day via DPD, with tracking sent to your phone. The Mounjaro KwikPen itself is compact and pre-filled, each pen contains four weeks of weekly doses, pre-set at the prescribed strength.

The price you see includes the consultation, the prescription, the medicine, and delivery. There are no subscription commitments. Before every repeat, a prescriber reviews your progress again, it is not a conveyor belt. If you are working toward a specific goal, our page on using weight loss injections to lose 1 stone sets out realistic timelines and what the evidence suggests you can expect. We also explain how the three main weight loss injections compare so you can go into your consultation with a clearer sense of the options. For context on how private treatment costs compare across the market, this page on injection pricing sets out what headline prices typically do and do not include. When you are ready to speak to a prescriber, you can start your free consultation here.